Cargando…

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trněný, Marek, Avigdor, Abraham, McKinney, Matthew S., Paneesha, Shankara, Wahlin, Björn E., Hrom, John S., Cunningham, David, Morley, Nicholas, Canales, Miguel, Bastos-Oreiro, Mariana, Belada, David, Devizzi, Liliana, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Jiang, Ping, Lynch, Ryan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469382/ https://www.ncbi.nlm.nih.gov/pubmed/37662520 http://dx.doi.org/10.1016/j.eclinm.2023.102130

Ejemplares similares

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
por: Hamadani, M., et al.
Publicado: (2022)

Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

The Citadel of the Senses
por: Brown, Robert K.
Publicado: (1986)

The Citadel of the Senses
por: Wilson, M. G.
Publicado: (1986)

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS
por: Sancho, J.-M., et al.
Publicado: (2022)

The citadel of freedom : a brief study of the Constitution and its builders, and of the movement to destroy it
por: Leigh, Randolph, 1891-
Publicado: (1924)

Breaking out of the citadel: social theory and psychiatry
por: Poole, Rob, et al.
Publicado: (2023)

A tale of two citadels: memoirs of a surgeon and his times
por: Williams, David Innes
Publicado: (1995)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

Criminals in the Citadel and Deceit all along the Watchtower: Irresponsibility, Fraud, and Complicity in the Search for Scientific Truth
por: Tharyan, Prathap
Publicado: (2012)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY
por: Zheng, Zhong, et al.
Publicado: (2023)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Analysis of medical student’s book reports on Cronin’s The Citadel: would young doctors give up ideals for prestige and wealth?
por: Hwang, Se Won, et al.
Publicado: (2016)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
por: Belada, D., et al.
Publicado: (2022)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Publicado: (2022)

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas
por: Dusílková, Nina, et al.
Publicado: (2017)

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2019)

ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2020)

Mutagenicity and carcinogenicity of combustion emissions are impacted more by combustor technology than by fuel composition: A brief review
por: DeMarini, David M., et al.
Publicado: (2022)

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
por: Procházka, Vít, et al.
Publicado: (2014)

Induction of mutation spectra by complex mixtures: approaches, problems, and possibilities.
por: DeMarini, D M
Publicado: (1994)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

LncRNA Rik-203 Contributes to Sevoflurane Induced Neurotoxicity?
por: Zhang, Lei, et al.
Publicado: (2020)

P1533: TRIAL IN PROGRESS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PARSACLISIB IN PATIENTS WITH PRIMARY WARM AUTOIMMUNE HEMOLYTIC ANEMIA
por: Barcellini, W., et al.
Publicado: (2022)

Schedule of experiment R203
por: Jarlskog, G
Publicado: (1973)

Quadrupole moment of $^{203}$Fr
por: Wilkins, S G, et al.
Publicado: (2017)

Synchronous Upper and Lower Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphomas
por: McFarlane, Michael, et al.
Publicado: (2016)

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
por: Mocikova, Heidi, et al.
Publicado: (2022)

Mutagenicity of the organic fraction of World Trade Center dust
por: DeMarini, David M., et al.
Publicado: (2022)

Entourage: the immune microenvironment following follicular lymphoma
por: Wahlin, B E, et al.
Publicado: (2012)

Reduced Intensity Allogeneic Stem Cell Transplant for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Lokare, Anand, et al.
Publicado: (2014)

Serenaden K. 185 & K. 203
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1990)

The decays of $^{205}$Po and $^{203}$Po
por: Astner, G, et al.
Publicado: (1972)

Health Tract No. 203: Household Knowledge
Publicado: (1865)

Health Tract No. 203: Household Knowledge
Publicado: (1864)

The Salmonella Mutagenicity Assay: The Stethoscope of Genetic Toxicology for the 21st Century
por: Claxton, Larry D., et al.
Publicado: (2010)

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY
por: Yacoub, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6l5u0u9m7655gboemt17jn67af